ArticlePLoS genetics2026
Multiple instance fine-mapping: Predicting causal regulatory variants with a deep sequence model.
Article in PLoS genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying causal genetic variants in a computational manner remains an open problem. Training end-to-end prediction models is not possible without large ground-truth datasets, while results of genome-wide association studies (GWAS) are entangled by linkage disequilibrium (LD), and gene expression datasets do not contain genetic variation at individual-level. Here, we propose Multiple Instance Fine-mapping (MIFM) - a multiple instance learning (MIL) objective to overcome the lack of strong labels by grouping putatively causal variants together based on their LD scores. Using MIFM, we trained a deep classifier on a dataset aggregating over 13,000 GWAS to predict causal variants based on their underlying DNA sequences. We validated variants prioritized by MIFM by constructing polygenic risk scores which transferred better to different target ancestries. Furthermore, we demonstrated how MIFM can be used to disentangle effect sizes of highly-correlated variants to better fine-map GWAS results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.